Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GNRHR | P30968 | 18/20 | 0.72 |
| ▸ | RXRA | P19793 | 2/20 | 0.67 |
| ▸ | FPR1 | P21462 | 1/20 | 0.61 |
| ▸ | GPR183 | P32249 | 1/20 | 0.61 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5835120 | 0.89 | GNRHR (0.67) | GNRHRRXRAFPR1GPR183GPR119 | |
| SCHEMBL5764021 | 0.87 | GNRHR (0.57) | GNRHRRXRAFPR1GPR183GPR119 | |
| SCHEMBL5834348 | 0.86 | GNRHR (0.68) | GNRHRFPR1GPR183GPR119 | |
| SCHEMBL5766856 | 0.86 | GNRHR (0.55) | GNRHRRXRAFPR1GPR183GPR119 | |
| SCHEMBL5762898 | 0.86 | GNRHR (0.55) | GNRHRRXRAFPR1GPR183GPR119 | |
| SCHEMBL5040244 | 0.81 | GNRHR (0.57) | GNRHRRXRAFPR1GPR183GPR119 | |
| SCHEMBL6226419 | 0.80 | GNRHR (0.68) | GNRHRFPR1GPR183GPR119 | |
| SCHEMBL6889150 | 0.80 | RXRA (1.00) | RXRA | |
| SCHEMBL24441357 | 0.79 | GNRHR (0.63) | GNRHRFPR1GPR183GPR119 | |
| SCHEMBL5835314 | 0.78 | GNRHR (1.00) | GNRHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7101878-B1 | Non-peptide GNRH agents, methods and intermediates for their preparation | AGOURON PHARMACEUTICALS, INC. (US) | 2006-09-05 | — | — | US | disclosed |
| EP-1334972-B1 | Non-peptide compounds affecting the action of gonadotropin-releasing hormone (GnRH) | PFIZER (US) | 2006-04-19 | — | — | EP | disclosed |
| US-20050250846-A1 | Non-peptide GnRH agents, pharmaceutical compositions and methods for their use | ANDERSON MARK B | 2005-11-10 | — | — | US | disclosed |
| EP-1560818-A1 | NON-PEPTIDE GNRH AGENTS, PHARMACEUTICAL COMPOSITIONS AND METHODS FOR THEIR USE | PFIZER INC. (US) | 2005-08-10 | — | — | EP | disclosed |
| US-6903132-B2 | Non-peptide GnRH agents, pharmaceutical compositions and methods for their use | AGOURON PHARMACEUTICALS, INC. (US) | 2005-06-07 | — | — | US | disclosed |
| EP-1105120-B1 | NON-PEPTIDE GnRH AGENTS, METHODS AND INTERMEDIATES FOR THEIR PREPARATION | AGOURON PHARMA (US) | 2005-03-23 | — | — | EP | disclosed |
| US-6833372-B2 | A hormone inhibitors of gonadotropin releasing hormone, an antigonadotropins, new drug compound contains a furanyl 2-carboxylic acid -(2,4-dimethoxy-pyrimidin-5-yl)-amide groups | PFIZER, INC. | 2004-12-21 | — | — | US | disclosed |
| US-20040053951-A1 | Non-peptide GnRH agents, pharmaceutical compositions, and methods for their use | PFIZER INC. | 2004-03-18 | — | — | US | disclosed |
| US-20040014787-A1 | Non-peptide GnRH agents, pharmaceutical compositions and methods for their use | AGOURON PHARMACEUTICALS, INC. | 2004-01-22 | — | — | US | disclosed |
| US-20040010033-A1 | Non-peptide GnRH agents, methods and intermediates for their preparation | PFIZER INC. | 2004-01-15 | — | — | US | disclosed |
| WO-2003106446-A1 | NON-PEPTIDE GNRH AGENTS, PHARMACEUTICAL COMPOSITIONS AND METHODS FOR THEIR USE | PFIZER INC. (US) | 2003-12-24 | — | — | WO | disclosed |
| WO-2003068769-A1 | NON-PEPTIDE COMPOUNDS AFFECTING THE ACTION OF GONADOTROPIN-RELEASING HORMONE (GNRH) | PFIZER INC. (US) | 2003-08-21 | — | — | WO | disclosed |
| EP-1334972-A1 | Non-peptide compounds affecting the action of gonadotropin-releasing hormone (GnRH) | PFIZER INC. (US) | 2003-08-13 | — | — | EP | disclosed |
| EP-1105120-A4 | NON-PEPTIDE GnRH AGENTS, METHODS AND INTERMEDIATES FOR THEIR PREPARATION | AGOURON PHARMA (US) | 2001-12-19 | — | — | EP | disclosed |
| EP-1105120-A2 | NON-PEPTIDE GnRH AGENTS, METHODS AND INTERMEDIATES FOR THEIR PREPARATION | AGOURON PHARMACEUTICALS, INC. (US) | 2001-06-13 | — | — | EP | disclosed |
| WO-2000020358-A2 | NON-PEPTIDE GnRH AGENTS, METHODS AND INTERMEDIATES FOR THEIR PREPARATION | AGOURON PHARMACEUTICALS, INC. (US) | 2000-04-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050250846-A1 | Non-peptide GnRH agents, pharmaceutical compositions and methods for their use | GNRHR, LHCGR, FSHR | GNRHR 1/4885RXRA 2092/4885FPR1 1988/4885 |
| US-20040014787-A1 | Non-peptide GnRH agents, pharmaceutical compositions and methods for their use | GNRHR, LHCGR, FSHR | GNRHR 1/4885RXRA 2092/4885FPR1 1988/4885 |
| US-20040010033-A1 | Non-peptide GnRH agents, methods and intermediates for their preparation | GNRHR, FSHR, LHCGR | GNRHR 1/4885RXRA 2376/4885FPR1 2087/4885 |
| US-20040053951-A1 | Non-peptide GnRH agents, pharmaceutical compositions, and methods for their use | GNRHR, LHCGR, FSHR | GNRHR 1/4885RXRA 1710/4885FPR1 1484/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.